Bronchopulmonary dysplasia (BPD) is a form of chronic lung disease of infancy, which mostly affects premature infants with significant morbidity and mortality. Premature infants who require to be treated for conditions including respiratory distress syndrome have a higher risk of developing BPD. In spite of the improvement in clinical methods, the incidence of BPD has not reduced. In the present review, the pathogenesis of BPD is described along with the treatments available at present and the role of nursing in the management of BPD. Emerging preventive therapies for BPD are also discussed, including the use of recombinant human superoxide dismutase, which has been proven effective in reducing respiratory injury and its long-term effects.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6257511 | PMC |
| http://dx.doi.org/10.3892/etm.2018.6780 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Elevated visfatin levels illuminate the inflammatory path in bronchopulmonary dysplasia.
Turk J Pediatr
December 2024
Department of Biochemistry, Faculty of Pharmacy, Ankara University, Ankara, Türkiye.
Background: Bronchopulmonary dysplasia (BPD) is a chronic lung disease in premature infants caused by an imbalance between lung injury and lung repair in the developing immature lungs of the newborn. Pulmonary inflammation is an important feature in the pathogenesis of BPD. The aim of this study was to evaluate the relationship between the inflammatory microenvironment and the levels of visfatin and nesfatin-1, which are among the new adipocytokines, in BPD patients.
View Article and Find Full Text PDFScoping review of initiation criteria for inhaled nitric oxide in preterm infants (born <34 weeks) after 7 days of age.
BMJ Open
December 2024
Research and Development Center for New Medical Frontiers, Department of Advanced Medicine, Division of Neonatal Intensive Care Medicine, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Objectives: Inhaled nitric oxide (iNO) is a known treatment for pulmonary hypertension (PH) associated with bronchopulmonary dysplasia in preterm infants after 7 days of age (postacute phase). However, a consensus regarding the optimal criteria for initiating iNO therapy in this population in the postacute phase is currently lacking. This study, therefore, aimed to identify the criteria for initiating iNO therapy, alongside the associated clinical and echocardiographic findings, in this population.
View Article and Find Full Text PDFHeart Rate Variability Does Not Predict Recurrence of Apnoea of Prematurity After Ceasing Caffeine Therapy: A Prospective Cohort Study.
Acta Paediatr
January 2025
Department of Neonatology, University Children's Hospital Basel UKBB, University of Basel, Basel, Switzerland.
Aim: We evaluated whether sample entropy of heart rate time series could serve as a biomarker for guiding caffeine cessation in preterm infants treated for apnoea of prematurity (AOP). We also assessed associations of sample entropy with weeks of gestation, clinical morbidity, AOP frequency and caffeine reinitiation.
Methods: We conducted a prospective single-centre study at the University Children's Hospital Basel, Switzerland, from July 2019 to June 2020.
Transition to competent oral feeding in preterm infants: Analyzing timing and determinants.
An Pediatr (Engl Ed)
January 2025
Departamento de Enfermería, Unidad de Neonatología, Hospital Universitario de Burgos, Burgos, Spain.
Introduction: The achievement of oral feeding competence (OFC) is a challenge in preterm infants and can be affected by several factors.
Objective: The aim of our study was to determine the time elapsed to development of OFC in very low birth weight (VLBW, weight <1500g) preterm infants and to identify factors associated with greater difficulty in achieving this skill.
Population And Methods: Observational, longitudinal and prospective study in VLBW infants over a period of 7 years (2016-2022).
Introduction: Pseudohypoparathyroidism 1A (PHP1A) is the best-known representative of inactivating PTH/PTHrP signaling disorders (iPPSD). The associated phenotype develops over time and often includes hormonal resistances, short stature and osteoma cutis. More complex and very early manifestations have also been reported.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!